These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34534357)

  • 21. Cumulative live birth rates between GnRH-agonist long and GnRH-antagonist protocol in one ART cycle when all embryos transferred: real-word data of 18,853 women from China.
    Yang J; Zhang X; Ding X; Wang Y; Huang G; Ye H
    Reprod Biol Endocrinol; 2021 Aug; 19(1):124. PubMed ID: 34384445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two gonadotropin-releasing hormone agonist suppression protocols for in vitro fertilization in young patients with low body mass index.
    Mu X; Cai H; Shi JZ
    Int J Gynaecol Obstet; 2023 Mar; 160(3):850-855. PubMed ID: 35900069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Endometrium Thickness on Clinical Outcomes in Luteal Phase Short-Acting GnRH-a Long Protocol and GnRH-Ant Protocol.
    Zhang J; Sun YF; Xu YM; Shi BJ; Han Y; Luo ZY; Zhao ZM; Hao GM; Gao BL
    Front Endocrinol (Lausanne); 2021; 12():578783. PubMed ID: 34079517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial.
    Youssef MA; van Wely M; Al-Inany H; Madani T; Jahangiri N; Khodabakhshi S; Alhalabi M; Akhondi M; Ansaripour S; Tokhmechy R; Zarandi L; Rizk A; El-Mohamedy M; Shaeer E; Khattab M; Mochtar MH; van der Veen F
    Hum Reprod; 2017 Jan; 32(1):112-118. PubMed ID: 27836979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled ovarian stimulation for endometriosis patients with ultra-long GnRH-agonist or GnRH-antagonist protocols: A retrospective study by propensity score matching.
    Chen Q; Du S; Lin Y; Zheng B
    J Obstet Gynaecol Res; 2023 May; 49(5):1366-1374. PubMed ID: 36780873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting clinical pregnancy in controlled ovarian hyperstimulation with GnRH-a long protocol: a retrospective cross-sectional study.
    Fan Y; Sun YF; Xu YM; Cao ZY; Luo ZY; Sun Y; Zhao ZM; Hao GM; Gao BL
    J Obstet Gynaecol; 2022 Aug; 42(6):2486-2491. PubMed ID: 35678767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.
    Albuquerque LE; Tso LO; Saconato H; Albuquerque MC; Macedo CR
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD002808. PubMed ID: 23440788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin improves live birth rates in POSEIDON group 3 and 4 expected poor responders.
    Tulek F; Kahraman A; Demirel LC
    Gynecol Endocrinol; 2022 Sep; 38(9):731-735. PubMed ID: 35856433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does oral contraceptives pretreatment affect the pregnancy outcome in polycystic ovary syndrome women undergoing ART with GnRH agonist protocol?
    Xu Z; Meng L; Pan C; Chen X; Huang X; Yang H
    Gynecol Endocrinol; 2019 Feb; 35(2):124-127. PubMed ID: 30303700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cumulative Live Birth Rates After the First ART Cycle Using Flexible GnRH Antagonist Protocol vs. Standard Long GnRH Agonist Protocol: A Retrospective Cohort Study in Women of Different Ages and Various Ovarian Reserve.
    Zhang W; Xie D; Zhang H; Huang J; Xiao X; Wang B; Tong Y; Miao Y; Wang X
    Front Endocrinol (Lausanne); 2020; 11():287. PubMed ID: 32457698
    [No Abstract]   [Full Text] [Related]  

  • 35. Pregnancy outcomes after controlled ovarian hyperstimulation in women with endometriosis-associated infertility: GnRH-agonist versus GnRH-antagonist.
    Kolanska K; Cohen J; Bendifallah S; Selleret L; Antoine JM; Chabbert-Buffet N; Darai E; d'Argent EM
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):681-686. PubMed ID: 28970135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of letrozole co-treatment on outcomes of gonadotropin-releasing hormone antagonist cycles in POSEIDON groups 3 and 4 expected poor responders.
    Kahraman A; Tulek F
    Arch Gynecol Obstet; 2022 Oct; 306(4):1313-1319. PubMed ID: 35833991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy.
    Merviel P; Cabry-Goubet R; Lourdel E; Devaux A; Belhadri-Mansouri N; Copin H; Benkhalifa M
    Reprod Health; 2015 May; 12():52. PubMed ID: 26025412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low dose clomiphene citrate as a mild stimulation protocol in women with unsuspected poor in vitro fertilization result can generate more oocytes with optimal cumulative pregnancy rate.
    Ochin H; Ma X; Wang L; Li X; Song J; Meng Y; Shen J; Cui YG; Liu J
    J Ovarian Res; 2018 May; 11(1):37. PubMed ID: 29728130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial.
    Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F
    Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.